Genomic Health Gets KO'd By Next-Gen Long-Term Breast Cancer Assays

20 Dec 2016

The new-generation of tests from Myriad and NanoString have outperformed Genomic Health's Oncotype Dx in predicting which breast cancer patients are at low-risk for a recurrence in five to ten years, and therefore do not need to be on extended endocrine therapy.

Results from the TransATAC trial show that Myriad Genetics Inc.'s EndoPredict and NanoString Technologies Inc.'s Prosigna second-generation tests are superior to Genomic Health Inc.'s Oncotype Dx first-generation test for predicting the long-term recurrence of breast cancer.

TransATAC “answers a critically important unmet need/question, which is how to we best manage patients with breast cancer after they've...